Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durable objective responses after MT-601 treatment Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc.

在加拿大不列颠哥伦比亚省惠斯勒举行的第十一届全球恶性血液病峰会上，来自希望之城国家医学中心淋巴瘤患者研究的初步数据显示，研究参与者对初始剂量水平的耐受性良好，并且在MT-601治疗后表现出持久的客观反应研究参与者在抗CD19 CAR T细胞治疗后复发的非霍奇金淋巴瘤在MT-601治疗后9个月仍保持完全反应休斯顿，2024年4月8日（环球新闻网）-Marker Therapeutics，Inc。

(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024).

（纳斯达克：MRKR）是一家临床阶段免疫肿瘤学公司，专注于开发新一代基于T细胞的免疫疗法，用于治疗血液系统恶性肿瘤和实体瘤适应症，今天报道称，加利福尼亚州杜阿尔特市希望之城国家医学中心的首席研究员杰弗里·舒斯博士应邀在加拿大不列颠哥伦比亚省惠斯勒市（2024年4月2日至7日）举行的第十一届全球血液系统恶性肿瘤峰会上介绍了他在阿波罗研究中的临床经验。

Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024. The Phase 1 APOLLO study is investigating MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 chimeric antigen receptor (CAR) T cell therapy.

Shouse博士概述了2024年4月6日（星期六）在希望之城获得的临床观察结果。阿波罗1期研究正在研究MT-601，一种多肿瘤相关抗原（multiTAA）特异性T细胞产物，用于治疗失败或不符合接受抗CD19嵌合抗原受体（CAR）T细胞治疗的淋巴瘤患者。

Marker previously reported that the first study participant tolerated the treatment well and achieved a complete response (CR) eight weeks after the second infusion of MT-601, which was maintained at the six months follow-up visit (Press Release, September 11, 2023). During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following.

Marker先前报道，第一名研究参与者对治疗耐受良好，并在第二次输注MT-601后8周达到完全缓解（CR），这在六个月的随访中得以维持（新闻稿，2023年9月11日）。在演示过程中，Shouse博士表示，该研究参与者在9个月后仍留在CR。